Litigation Details for Eli Lilly and Company v. Teva Pharmaceuticals USA Inc (W.D. Wash. 2017)
✉ Email this page to a colleague
Eli Lilly and Company v. Teva Pharmaceuticals USA Inc (W.D. Wash. 2017)
Docket | ⤷ Try a Trial | Date Filed | 2017-02-01 |
Court | District Court, W.D. Washington | Date Terminated | 2017-02-20 |
Cause | Assigned To | Robert S. Lasnik | |
Jury Demand | Referred To | ||
Patents | 6,943,166 | ||
Link to Docket | External link to docket |
Small Molecule Drugs cited in Eli Lilly and Company v. Teva Pharmaceuticals USA Inc
Details for Eli Lilly and Company v. Teva Pharmaceuticals USA Inc (W.D. Wash. 2017)
Date Filed | Document No. | Description | Snippet | Link To Document |
---|---|---|---|---|
2017-02-01 | 1 | 17 Decl. at ¶ 3.) The patent-in-suit—U.S. Patent No. 6,943,166 (“’166 patent”)—is entitled 18 “Compositions…named co-inventor 23 of the ’166 patent. (See Dkt. No. 1-1, ’166 Patent at Cover Page; Stewart Decl. at…contemplation of filing a patent 12 application or other document with the [Patent and Trademark] Office…corporation’s patent attorney that an invention has been made and to initiate patent action.” In re…discoverable in a patent case, if those materials relate to an issue of substantive patent law.” Advanced | External link to document | |
>Date Filed | >Document No. | >Description | >Snippet | >Link To Document |